Previous 10 | Next 10 |
Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies PR Newswire If authorized, Zokinvy® (lonafarnib) will be the first and only treatment approved in Europe ...
Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan PR Newswire PALO ALTO, Calif. and OSAKA, Japan , May 10, 2022 /PRNewswire/ -- Eiger Biopharmaceutica...
Eiger BioPharmaceuticals, Inc. (EIGR) Q1 2022 Earnings Conference Call May 5, 2022 04:30 PM ET Company Participants Sarah Mathieson - Senior Vice President-Corporate Affairs David Cory - President & Chief Executive Officer Ingrid Choong - Senior Vice President-Clinical Development Eldon M...
The following slide deck was published by Eiger BioPharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Eiger BioPharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation
Eiger BioPharmaceuticals press release (NASDAQ:EIGR): Q1 GAAP EPS of -$0.64 in-line. Revenue of $2.67M (-26.8% Y/Y) misses by $1.38M. For further details see: Eiger BioPharmaceuticals GAAP EPS of -$0.64 in-line, revenue of $2.67M misses by $1.38M
Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update PR Newswire Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022 Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End ...
Eiger BioPharmaceuticals (NASDAQ:EIGR) said a study showed that avexitide significantly reduced the likelihood of fasting and protein-induced hypoglycemia in patients with congenital hyperinsulinism (HI). HI is a a genetic disorder and common cause of persistent hypoglycemia (low bl...
Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program PR Newswire - Phase 2 study demonstrating avexitide significantly reduced hypoglycemia in children with congenital hyp...
Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5 PR Newswire - Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif. , April 21, 2022 /PRNewswire/ --&...
Eiger BioPharmaceuticals (NASDAQ:EIGR) appoints Christopher Kurtz as Chief Technical Officer and Sarah Mathieson as Senior Vice President, Corporate Affairs. Previously, Chris served as Executive Vice President of Technical Operations at Cidara Therapeutics where he established and valid...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...